At-home HPV testing has been approved by the FDA and is being widely marketed as a breakthrough in cervical cancer screening—offering convenience, privacy, and accessibility. But as enthusiasm grows, so do important questions.

Can at-home HPV testing truly replace the Pap test? What cancers might be missed? And how should women and clinicians thoughtfully integrate this new option into evidence-based care?

In this episode of Sky Women’s Health, Dr. Carolyn Moyers talks with Dr. Richard Hopley, pathologist and Director of Clinical Pathology at PathAdvantage, to unpack what the headlines aren’t telling you about FDA-approved at-home HPV tests.

We discuss why HPV-only testing sounds appealing, what it does well, and where it falls short—especially when used as a replacement for the Pap test.

Why This Matters to You

* HPV testing alone can miss some cervical cancers—even with a negative result

* Certain at-home tests detect transient infections, increasing anxiety and unnecessary procedures

* The Pap test still provides critical information HPV tests cannot

* Convenience should never come at the cost of missed or delayed diagnoses

What You’ll Learn

* Who at-home HPV testing may help—and who it may not

* Why many experts still recommend Pap + HPV co-testing

* How to interpret HPV results without panic

* How to make informed screening decisions that prioritize long-term health

Bottom line: At-home HPV testing may expand access, but it does not replace comprehensive gynecologic care. Knowing the limits of new technology helps you protect your health—without relying on headlines alone.

https://www.pathadvantage.com/at-home-hpv-testing-promise-or-peril/

🔗 Connect with Dr. Carolyn Moyers

📸 Instagram: @drcarolynmoyers

🎥 YouTube: @drcarolynmoyers

🌐 Website: www.skywomenshealth.com

Episode 233: At-Home HPV Testing: Promise or Peril in a New Screening Era